D
12.66
-0.01 (-0.08%)
Penutupan Terdahulu | 12.67 |
Buka | 12.75 |
Jumlah Dagangan | 327,831 |
Purata Dagangan (3B) | 393,891 |
Modal Pasaran | 418,019,264 |
Harga / Pendapatan (P/E Ke hadapan) | 86.21 |
Harga / Jualan (P/S) | 7.50 |
Harga / Buku (P/B) | 5.45 |
Julat 52 Minggu | |
Tarikh Pendapatan | 24 Mar 2025 - 28 Mar 2025 |
Margin Keuntungan | -26.38% |
Margin Operasi (TTM) | 3.24% |
EPS Cair (TTM) | -0.450 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 530.30% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 1.27% |
Nisbah Semasa (MRQ) | 15.95 |
Aliran Tunai Operasi (OCF TTM) | -6.89 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.11 M |
Pulangan Atas Aset (ROA TTM) | -1.51% |
Pulangan Atas Ekuiti (ROE TTM) | -28.13% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Medical Devices (US) | Menurun | Menurun |
Medical Devices (Global) | Menurun | Menurun | |
Stok | Delcath Systems, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.5
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 1.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | -0.5 |
Purata | 1.50 |
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. |
|
Sektor | Healthcare |
Industri | Medical Devices |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 2.73% |
% Dimiliki oleh Institusi | 45.01% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 29.00 (HC Wainwright & Co., 129.07%) | Beli |
Median | 27.00 (113.27%) | |
Rendah | 25.00 (Stephens & Co., 97.47%) | Beli |
Purata | 27.00 (113.27%) | |
Jumlah | 2 Beli | |
Harga Purata @ Panggilan | 14.69 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Stephens & Co. | 23 Jun 2025 | 25.00 (97.47%) | Beli | 13.26 |
HC Wainwright & Co. | 23 May 2025 | 29.00 (129.07%) | Beli | 16.11 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
22 May 2025 | Pengumuman | Delcath Systems Issues Full Year 2025 Guidance |
15 May 2025 | Pengumuman | Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference |
09 May 2025 | Pengumuman | Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
08 May 2025 | Pengumuman | Delcath Systems Reports First Quarter 2025 Results and Business Highlights |
28 Apr 2025 | Pengumuman | Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer |
24 Apr 2025 | Pengumuman | Delcath Systems to Host First Quarter 2025 Earnings Call |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |